Drug intelligence / Profile preview

influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal)

Development stage
Approved
Lead developer
MedImmune
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Intranasal
01

Overview

Trivalent inactivated influenza vaccine (TIV) and FluMist are two distinct types of flu vaccines. TIV is an injectable vaccine containing three inactivated (killed) strains of the influenza virus—typically one A(H1N1), one A(H3N2), and one B lineage strain. It works by stimulating the immune system to produce antibodies against these viral proteins without causing disease. TIV is administered via intramuscular injection and is suitable for a wide range of age groups[1][3][7]. FluMist is a brand name for the live attenuated influenza vaccine (LAIV), which contains weakened but live forms of the same three or four strains found in other flu vaccines. It is delivered as a nasal spray and induces immunity by mimicking natural infection at mucosal surfaces where respiratory viruses enter[4][6]. FluMist stimulates both mucosal and systemic immune responses. TIV has been widely used for decades; LAIV/FluMist was developed as an alternative for those who prefer needle-free vaccination or have needle phobia. Both are indicated primarily for prevention of seasonal influenza.

Brand names
FluMist
Other names
TIVtrivalent inactivated influenza vaccineLAIVlive attenuated influenza vaccine
02

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call